Year: 2021

Results for the Third Quarter of 2021:Net loss attributable to the company of $59.6 million, or ($1.18) per diluted share Adjusted EBITDA of ($14.8) million Consolidated crush margin of $0.01 per gallon for the third quarter and $0.16 per gallon year-to-date Cash, cash equivalents and restricted cash of $720.9 million with $312.6 million available under committed credit facilitiesHighlights and Recent DevelopmentsGreen Plains Wood River LLC’s MSC™ Ultra-High Protein system is operational, with shipments expected in November Broke ground on 4th MSC™ Ultra-High Protein facility, at Green Plains Mount Vernon, and anticipate breaking ground at Obion, Green Plains’ 5th MSC™ location in the coming weeks Extended sales commitments to our pet food vertical with higher volumes through 2022 with a signed MOU for additional sales through 2023...

– Robust In Vivo Data Presented at Scientific Meetings Support Advancement of Dyne’s Co-lead Candidates into the Clinic – – Investigational New Drug (IND) Submissions Anticipated for DYNE-251 in DMD During the Fourth Quarter of 2021 and for DYNE-101 in DM1 During the First Quarter of 2022 – WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2021 and business highlights. “We made tremendous progress during the third quarter and are now preparing to advance Dyne’s two co-lead programs into the clinic, with the IND submission for DYNE-251 in DMD anticipated during the fourth quarter...

Exodus to Retire up to $2 million in Class A Common Stock, up to $55 per share OMAHA, Neb., Nov. 04, 2021 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (tZERO ATS: EXOD), (“the Company” or “Exodus”) the leading non-custodial cryptocurrency software platform, today announced its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $2 million of its outstanding shares of Class A common stock. “The share repurchase program demonstrates our confidence in the growth trajectory of Exodus,” said JP Richardson, CEO and co-founder of Exodus. “Our treasury has expanded greatly over the past six months. We have seen exceptionally strong year-over-year financial performance as well as significant increases in the market value of our digital asset holdings. As such, we are in a position to return...

ATLANTA, Nov. 04, 2021 (GLOBE NEWSWIRE) — Speedemissions, Inc. (OTC Markets Expert Market: SPMI) (the “Company”) a retail brand emissions testing and safety inspections company, operating nineteen stores in the Atlanta and St. Louis markets, today announces its financial results for the third quarter ended September 30, 2021. “Our third quarter showed solid progress in the overall operation of the business as we produced a positive EBITDA1 for the 11th consecutive quarter,” stated Rich Parlontieri, Speedemissions CEO & President. “It is a testament to the commitment and hard work provided by our employees and executive team and demonstrates that the collaborative decisions we have made continue to move Speedemissions in the right direction.” “While we remain focused on the continual advancement of our core business, these...

ALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2021 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO and president, will present at the Jefferies London Healthcare Conference. The presentation is scheduled for Wednesday, November 17, 2021 at 4:25 p.m. (11:25 a.m. ET). The presentation will be webcast live and accessible through the Investors page at www.axogeninc.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.axogeninc.com. About AxogenAxogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration...

– Commenced enrollment in tumor-specific monotherapy and pimivalimab combination expansion cohorts of INNATE trial of JTX-8064 – – Ended the quarter with $249.0 million in cash, cash equivalents and investments – – Company to host conference call and webcast today at 8:00 AM ET – CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. “Jounce has had another very productive quarter as we have made significant progress across all areas of the company and continue to build momentum as we head into the new year. We were pleased...

NORCROSS, Ga., Nov. 04, 2021 (GLOBE NEWSWIRE) — Intelligent Systems Corporation [NYSE: INS], the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter ended September 30, 2021. “Our strong performance in the first half of 2021 continued into the third quarter, and as a result, we now expect top-line growth of 30% to 35% for the full year,” said Leland Strange, CEO of Intelligent Systems. “We recognized $1.8 million in license revenue in the quarter, while also growing professional services and processing and maintenance revenue. Total revenue in the quarter was $12.9 million, a 26% increase year-over-year.” “Additionally, we continued making strategic investments that enable us to...

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that management will participate in several virtual investor conferences in November 2021. Details are as follows: Conference: BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in OncologyPanel; Emerging Trends in Oncology: Targeted Therapies and Other Novel Treatment ModalitiesDate: Monday, November 8, 2021, 3:25pm EST; available for replay following the event Conference: Credit Suisse 30th Annual Healthcare ConferenceFireside Chat; Investor MeetingsDate: Thursday, November 11, 2021, 3:30pm EST; live and available for replayWebcast Link Conference: Stifel 2021 Virtual Healthcare ConferenceCorporate Presentation; Investor...

–On-track to initiate enrollment by year-end in Phase 1b clinical trial of FTX-6058 in people with sickle cell disease– – Losmapimod update planned for Q1 2022 – –Raised $144.2 million in gross proceeds from August 2021 public offering, extending cash runway into 2024 – – Conference call scheduled for 8:00 a.m. ET today – CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the third quarter of 2021. “Fulcrum made great progress in the third quarter, as we continued to advance our lead programs for FSHD and sickle cell disease,” said Bryan Stuart, president and chief executive officer. “Most notably,...

Increased Revenue 20% Year-Over-Year to $48.2 Million Net Income of $5.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the third quarter ended September 30, 2021 with record revenue of $48.2 million and net income of $5.4 million, or $0.03 per basic and diluted earnings per share. Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, “Our third quarter financial and operating results are illustrative of the strong execution that we continue to deliver across our diversified business. While XYOSTED and Teva’s generic EpiPen remain the chief drivers of the 20% revenue growth this quarter, we also advanced...